Low-dose Glucocorticoid Vasculitis Induction Study

Related Clinical Trial
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Low-dose Glucocorticoid Vasculitis Induction Study

Official Title

Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial

Brief Summary

      Previous reports suggested conventional immunosuppressants such as cyclophosphamide could not
      reduce glucocorticoid dose in remission induction in ANCA-associated vasculitis because of
      lower remission rate and higher relapse rate. However those reports didn't include rituximab.

      B cell depletion therapy by rituximab is a new strategy for remission induction in
      ANCA-associated vasculitis. The RAVE and RITUXVAS trial (NEJM 2010, both) showed high-dose
      glucocorticoid plus rituximab had roughly the same efficacy and safety as high-dose
      glucocorticoid plus IV-cyclophosphamide. In addition, recent retrospective observational
      studies reported low-dose glucocorticoid plus rituximab led to re-induction in severe
      relapsing ANCA-associated vasculitis.

      Thus, the investigators aim to investigate whether rituximab can reduce glucocorticoid dose
      in induction remission in ANCA-associated vasculitis (to show non-inferiority for efficacy
      between low-dose and high-dose glucocorticoid plus rituximab). Participants will be
      randomised to the "low-dose glucocorticoid plus rituximab" or the high-dose glucocorticoid
      plus rituximab" groups. Primary endpoint is proportion of remission at 6 months, then data
      regarding relapse and long-term safety will be collected until 24 months.

      The study has been designed by the principal and coordinating investigators. It will include
      140 participants from 18 hospitals in Japan. It is funded by Chiba University Hospital and
      Chiba East Hospital.
    

Detailed Description

      ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis is characterised by small
      vessel vasculitis and presence of autoantibodies, ANCA. It can be a life-threatening disease
      with renal/respiratory failure. Current standard therapy in induction remission for
      ANCA-associated vasculitis is combination of high-dose glucocorticoid and
      IV-cyclophosphamide. This regimen is effective (remission rate; 80-90%), but often cause
      various glucocorticoid-related side effects. Especially, infection is related to death. Thus
      a new regimen reducing glucocorticoid dose is required.
    

Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

Proportion of the patients achieving remission

Secondary Outcome

 Time to remission

Condition

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Intervention

Rituximab

Study Arms / Comparison Groups

 Low-dose glucocorticoid
Description:  Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).
After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

140

Start Date

October 2014

Completion Date

June 2021

Primary Completion Date

December 2019

Eligibility Criteria

        Inclusion Criteria:

          1. Provision of written informed consent by a patient or a surrogate decision maker

          2. Age=>20 years

          3. New clinical diagnosis of ANCA-associated vasculitis (granulomatosis with
             polyangiitis, microscopic polyangiitis or renal limited ANCA-associated vasculitis)
             consistent with the 2012 Chapel Hill consensus definitions

          4. Positive test by ELISA for proteinase 3-ANCA or myeloperoxidase-ANCA

        Exclusion Criteria:

          1. Prior treatment for ANCA-associated vasculitis before trial entry

          2. ANCA-associated vasculitis related glomerulonephritis (eGFR<15ml/min) or alveolar
             hemorrhage (oxygen inhalation >2L/min)

          3. Presence of another multisystem autoimmune disease

          4. Known infection with HIV; a past or current history of hepatitis B virus or hepatitis
             C virus infection

          5. Desire to bear children, pregnancy or lactating

          6. History of malignancy within the past 5 years or any evidence of persistent malignancy

          7. Ongoing or recent (last 1 year) evidence of active tuberculosis

          8. Severe allergy or anaphylaxis to monoclonal antibody therapy

          9. Any concomitant condition anticipated to likely require oral systemic glucocorticoids,
             immunosuppressants, biologics, plasma exchange or IVIg

         10. Any biological B cell depleting agent (such as rituximab or belimumab) within the past
             6 months

         11. Other conditions, in the investigator's opinion, inappropriate for the trial entry
      

Gender

All

Ages

20 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Hiroshi Nakajima, M.D., Ph.D, , 

Location Countries

Japan

Location Countries

Japan

Administrative Informations


NCT ID

NCT02198248

Organization ID

G25051

Secondary IDs

UMIN000014222

Responsible Party

Principal Investigator

Study Sponsor

Chiba University


Study Sponsor

Hiroshi Nakajima, M.D., Ph.D, Principal Investigator, Chiba University Hospital


Verification Date

January 2021